Accessibility Menu

iTonic(NASDAQ) PTHL

Current PriceN/A
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-93%
5 YearN/A
1 Year-99%
1 Month-19%
iTonic last closing stock price
MetricPriceDate
Last closeUSD 0.272026-07-24
iTonic stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.13%USD 0.282026-07-17
1 month-18.56%USD 0.332026-06-24
3 month-29.14%USD 0.372026-04-24
Year to date-37.02%USD 0.422025-12-31
1 year-99.07%USD 28.422025-07-24
Since inception-92.99%USD 3.782024-09-05

iTonic Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$877.51K

Net Income (TTM)

-$2.86M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

PTHL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About iTonic

Pheton Holdings Ltd is a specialized healthcare enterprise focused on developing and commercializing software and devices integral to brachytherapy treatments. The company offers a proprietary treatment planning system designed to enhance radiation therapy for cancer patients.

Products and Services
  • Proprietary treatment planning system for brachytherapy
  • Advanced software for precise dose distribution in oncology
  • Devices designed to improve cancer treatment outcomes
Growth Outlook
  • Significant revenue growth from $67,507 in Q2 2025 to $237,708 in Q4 2024
  • Improved gross profit margin from 79% in Q2 2025 to 84% in Q4 2024
  • Strong cash position with $6.16 million in cash and short-term investments as of Q4 2024
Financial Highlights
  • Trailing twelve months (TTM) revenue of $1.1 million
  • Current ratio of 8.83 indicates strong liquidity
  • Net income loss reduced from $2.04 million in Q2 2025 to $0.33 million in Q4 2024
Pheton Holdings Ltd operates in the medical devices sector, specifically targeting the oncology market with innovative solutions. The proprietary treatment planning system, known as FTTPS, is engineered to optimize brachytherapy treatments, which are crucial for targeting malignant tumors effectively. Established in 1998 and headquartered in Beijing, the company has positioned itself as a key player in the healthcare industry. The growth outlook for Pheton Holdings Ltd appears promising, with a notable increase in revenue and improvements in gross profit margins. The company's strong liquidity, as indicated by a current ratio of 8.83, suggests it is well-equipped to manage its short-term obligations. Furthermore, the reduction in net income loss over recent quarters reflects operational improvements and a potential path toward profitability. Investors may find Pheton Holdings Ltd an intriguing opportunity within the healthcare sector, particularly given its focus on advanced cancer treatment technologies and the positive trends in its financial performance.
AI Generated • Jul 20, 2026

Industry

Health Care Technology

Sector

Health Care

CEO

Jian Fei Zhang

Website

www.ftzy.com.cn

Headquarters

Beijing, CN

PTHL Financials

Key Financial Metrics (TTM)

Gross Margin

62.59%

Operating Margin

-991.71%

Net Income Margin

-974.68%

Return on Equity

-93.93%

Return on Capital

-11.97%

Return on Assets

-56.04%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$706.26K

Operating Income

-$3.06M

EBITDA

-$3.00M

Operating Cash Flow

-$3.63M

Capital Expenditure

-$3.60K

Free Cash Flow

-$3.63M

Cash & ST Invst.

$3.21M

Total Debt

$139.60K

iTonic Performance Analysis

iTonic annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 679,777-3.3%
20232023-12-31USD 628,591-7.5%
20242024-12-31USD 448,196-28.7%
20252025-12-31USD 523,03116.7%
iTonic sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31171.2%
Q22024-06-30-41.8%
Q42024-12-3112.9%
Q22025-06-30-71.6%
iTonic annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.01-56.4%
20232023-12-31USD -0.02N/A
20242024-12-31USD -0.05212.7%
20252025-12-31USD -0.32512.5%
iTonic sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31-87.9%
Q22024-06-30-80.7%
Q42024-12-31-33.5%
Q22025-06-30-432.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$67.51K

-49.4%

Gross Profit

$53.35K

-46.4%

Gross Margin

79.03%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

10

N/A

Net Income

-$2.04M

-4774.4%

EBITDA

-$2.03M

-4306.3%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$3.21M

+9481.3%

Total Debt

$139.60K

-24.4%

Accounts Receivable

$185.46K

-47.3%

Inventory

$126.60K

+9.1%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$139.60K

+155.6%

Return on Assets

-56.04%

N/A

Return on Invested Capital

-60.08%

N/A

Free Cash Flow

-$2.84M

-18279.1%

Operating Cash Flow

-$2.84M

-18261.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IINNInspira Technologies Oxy B.H.N. Ltd.
$0.91-23.22%
LFWDLifeward Ltd.
$7.05+0.28%
SINTSintx Technologies, Inc.
$1.40-7.89%
BMRABiomerica, Inc.
$1.59-0.94%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
TAT&T
$24.13+0.05%

Questions About PTHL

What is the current price of iTonic?

iTonic is trading at N/A per share.

What is the 52-week range for iTonic?

Over the past 52 weeks, iTonic has traded between N/A and N/A.

How much debt does iTonic have?

As of the most recent reporting period, iTonic reported total debt of $143.00K.

How much cash does iTonic have on hand?

iTonic reported $1.49M in cash and cash equivalents in its most recent financial results.

What is iTonic’s dividend yield?

iTonic does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services